Related Experiment Videos
Implications of troponin testing in clinical medicine
Britta U Goldmann1, Robert H Christenson, Christian W Hamm
1University Hospital Eppendorf, Division of Cardiology, Hamburg, Germany. goldmann@uke.uni-hamburg.de
Insights
Cardiac troponins are now essential for assessing risk in patients with chest pain, surpassing older markers like creatine kinase-MB for diagnosing myocardial infarction. Their levels help guide treatment, even when the cause of heart damage is unclear.
Area of Science:
- Cardiology
- Biomarker Discovery
Background:
- Cardiac troponins have emerged as crucial biomarkers in cardiology over the past decade.
- Risk stratification in acute chest pain is as vital as diagnosing myocardial infarction (MI).
- Creatine kinase (CK)-MB, once the gold standard, has been replaced by more accurate troponin assays.
Purpose of the Study:
- To review the diagnostic and risk stratification capabilities of cardiac troponins in patients with acute chest pain.
- To highlight the role of troponins in assessing ischaemic heart disease and guiding therapeutic strategies.
Main Methods:
- Review of research on cardiac troponin assays and their clinical applications.
- Analysis of troponin's role in diagnosing myocardial infarction and other cardiac conditions.
- Evaluation of troponin's prognostic value regardless of the underlying cause of myocardial damage.
Main Results:
- Cardiac troponin measurements are a key factor in assessing ischaemic heart disease.
- Troponin release indicates thrombus formation and embolization, informing the use of antithrombotic therapies.
- Elevated troponins are highly sensitive and specific for myocardial damage but can result from various conditions.
Conclusions:
- Clinicians increasingly rely on troponin assays for personalized treatment plans due to their prognostic significance.
- Troponin assays are indispensable tools for managing patients with suspected or confirmed cardiac events.
- Understanding troponin's role aids in optimizing patient outcomes in acute and chronic cardiovascular disease.
Abstract:
During the past decade considerable research has been conducted into the use of cardiac troponins, their diagnostic capability and their potential to allow risk stratification in patients with acute chest pain. Determination of risk in patients with suspected myocardial ischaemia is known to be as important as retrospective confirmation of a diagnosis of myocardial infarction (MI). Therefore, creatine kinase (CK)-MB - the former 'gold standard' in detecting myocardial necrosis - has been supplanted by new, more accurate biomarkers.Measurement of cardiac troponin levels constitute a substantial determinant in assessment of ischaemic heart disease, the presentations of which range from silent ischaemia to acute MI. Under these conditions, troponin release is regarded as surrogate marker of thrombus formation and peripheral embolization, and therefore new therapeutic strategies are focusing on potent antithrombotic regimens to improve long-term outcomes. Although elevated troponin levels are highly sensitive and specific indicators of myocardial damage, they are not always reflective of acute ischaemic coronary artery disease; other processes have been identified that cause elevations in these biomarkers. However, because prognosis appears to be related to the presence of troponins regardless of the mechanism of myocardial damage, clinicians increasingly rely on troponin assays when formulating individual therapeutic plans.